Avantor, Inc.

Avantor, Inc.

AVTR
Avantor, Inc.US flagNew York Stock Exchange
13.71
USD
-0.14
- -
9.27BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.41
2.51
11.81
15.06
11.09
12.51
11.54
10.31
9.98
9.63
9.68
Basic EPS, GAAP
-0.09
-0.23
-0.72
-0.29
0.09
0.86
1.02
0.48
1.05
-0.78
-0.85
Free Cash Flow per Basic Share
0.15
-0.34
0.4
0.88
1.61
1.61
1.3
1.29
1.24
0.92
0.88
Dividend per Share
0.32
3.43
- -
0.08
0.11
0.11
0.05
- -
- -
- -
- -
Book Value per Share
- -
-6.14
-7.16
2.55
2.88
5.24
7.2
7.76
8.75
8.16
8.32
Tangible Book Value per Share
- -
-24.52
-24.39
-9.66
-9.03
-11.95
-7.31
-6.27
-4.32
-3.84
-3.43
Basic Weighted Avg Shares
491
496
496
401
576
590
651
676
680
681
678
Sales/Revenue/Turnover
691
1,247
5,864
6,040
6,394
7,386
7,512
6,967
6,784
6,552
6,561
Operating Margin (%)
1.43
-16.87
7.05
9.14
11.05
13.16
15.04
12.3
9.41
8.3
7.45
Depreciation Expense
60
99
405
399
395
379
406
402
406
410
418
Net Income, GAAP
-42
-113
-87
38
117
573
686
321
712
-530
-578
Effective Tax Rate (%)
- -
- -
- -
6.9
- -
23.96
19.34
21.78
16.68
- -
110.21
Profit Margin (%)
-6.13
-9.03
-1.48
0.63
1.82
7.75
9.14
4.61
10.49
-8.09
-8.81
Working Capital
- -
730
803
947
988
1,026
999
905
139
1,072
1,080
LT Debt
- -
7,009
6,782
5,023
4,868
6,978
5,923
5,277
3,235
3,916
3,661
Total Equity
- -
-2,620
-3,052
2,462
2,674
4,197
4,855
5,253
5,957
5,565
5,630
Return on Invested Capital (%)
- -
- -
- -
9
- -
7.89
8.17
6.13
5.13
- -
- -
Return on Capital (%)
- -
- -
- -
7.81
- -
7.86
8.06
4.96
8.59
- -
-2.4
Return on Common Equity (%)
- -
- -
- -
- -
3.32
20.89
16.46
6.35
12.69
-9.2
-9.7

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
31
37
37
LT Borrowings
3,916
3,779
3,661
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
682
683
676
Market Capitalization
7,816
5,354
6,697

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,451
2,404
2,462
Cash, Cash Equivalents & STI
365
279
307
Accounts Receivable, Net
1,075
1,105
1,139
Inventories
818
810
829
Total Current Liabilities
1,379
1,367
1,382
Payables & Accruals
789
767
789
ST Debt
31
37
37
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
17.53%
-6.58%
Free Cash Flow
- -
-7%
-25.81%
Net Income, GAAP
- -
60.96%
-174.52%
Sales/Revenue/Turnover
- -
0.78%
-3.41%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,680
1,703
1,714
1,687
6,784
2025
1,581
1,683
1,624
1,664
6,552
2026
1,581
1,692
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.14
0.08
0.74
1.05
2025
0.09
0.09
-1.04
0.08
-0.78
2026
0.06
0.06
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Emmanuel Ligner
Full Time Employees
13,500
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
Radnor Corporate Center Radnor PA United States of America 19087
IPO Date
May 17, 2019
Business
Avantor, Inc. (NYSE: AVTR) is a leading global provider of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries; the company offers a broad portfolio encompassing materials and consumables such as ultra-high purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, process chromatography resins and columns, analytical sample prep kits, education and microbiology kits, and clinical trial kits; equipment and instrumentation including filtration systems, virus inactivation systems, incubators, peristaltic pumps, fluid handling tips, and analytical instruments; and services and specialty procurement such as onsite lab and production services, equipment procurement and sourcing, biopharmaceutical material scale-up and development, procurement and material management, general lab services, technical lab services, production services, downstream optimization, and business process consulting. Operating through two primary segments—Laboratory Solutions and Bioscience Production—Avantor supports applications in monoclonal antibodies, recombinant proteins, gene therapies, vaccines, cell therapies, mRNA vaccines and therapies, fluid handling technologies, buffer management, and small molecule products, with a global footprint spanning over 30 countries across the Americas, Europe, and AMEA regions and access to more than 300,000 customer locations. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company maintains an integrated business model with extensive manufacturing, distribution, and sales centers worldwide. Recent developments include the appointment of Emmanuel Ligner as President and CEO to drive growth and value creation in life sciences; divestiture of its clinical services business to Audax Private Equity for $650 million in 2025, rebranded as Resonant Clinical Solutions, to sharpen focus on lab and production businesses while generating approximately $500 million in after-tax cash proceeds for debt reduction; expansion of centralized service center model with a new Boston-area facility featuring specialized glassware washing and autoclaving; a strategic partnership with p-Chip Corporation announced in October 2025 to develop solutions for secure chain-of-identity, enhanced traceability, and digital process control in pharmaceutical and clinical manufacturing; and a significant capacity expansion at its European manufacturing site to quadruple production for biologics and therapies.

Company News

APIChatGPT
  • Are Medical Stocks Lagging Avantor (AVTR) This Year?

  • Avantor, Inc. (AVTR) Just Flashed Golden Cross Signal: Do You Buy?

  • Bank of Nova Scotia Has $326,000 Stock Holdings in Avantor, Inc. $AVTR

  • Avantor Q2 Earnings Beat Estimates on VWR Growth, Guidance Raised

  • Avantor (NYSE:AVTR) Shares Gap Up Following Earnings Beat

  • Avantor Q2 Earnings Call Highlights

  • Oil Spikes 7%, Nasdaq 100 Sinks Before Fed: Stock Market Today

  • Avantor, Inc. (AVTR) Q2 2026 Earnings Call Transcript

  • Avantor (AVTR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

  • Avantor, Inc. (AVTR) Beats Q2 Earnings and Revenue Estimates

  • Avantor® Reports Second Quarter 2026 Results

  • Avantor, Inc. (AVTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

  • AVTR vs. ICLR: Which Stock Should Value Investors Buy Now?

  • Will Avantor (AVTR) Beat Estimates Again in Its Next Earnings Report?

  • Avantor Stock Up on NuSil's Expanded HIV Prevention Partnership

  • Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product

  • Here's Why You Should Hold Avantor Stock in Your Portfolio for Now

  • Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026

  • Why Is Avantor (AVTR) Up 13% Since Last Earnings Report?

  • Here's Why You Should Hold Avantor Stock in Your Portfolio for Now